# Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy

> **NCT03352076** · PHASE2 · COMPLETED · sponsor: **Viramal Limited** · enrollment: 30 (actual)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Vaginal Danazol
- **DRUG:** Oral Danatrol

## Key facts

- **NCT ID:** NCT03352076
- **Lead sponsor:** Viramal Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-28
- **Primary completion:** 2019-10-24
- **Final completion:** 2020-05-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352076, "Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03352076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*